Final plozasiran data from the open label extension (OLE) of the Phase 2 SHASTA trial in patients with severe hypertriglyceridaemia (HTG) and the MUIR trial in patients with moderate HTG have demonstrated robust and sustained TG lowering with a favourable safety profile, concluded Professor Christie Ballantyne and investigators.
